Inhaled salmeterol/fluticasone propionate combination: A pharmacoeconomic review of its use in the management of asthma

PharmacoEconomics

Volumn 18, Issue 6, 2000, Pages 591-608

  Markham, Anthony ^a   Adkins, Julie C ^a   Jarvis, Blair ^b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; SALBUTAMOL;

ANALYTIC METHOD; ARTICLE; ASTHMA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEVELOPED COUNTRY; DRUG COST; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TOLERABILITY; DRY POWDER; ECONOMIC ASPECT; HUMAN; INTERMETHOD COMPARISON; MONOTHERAPY; MORBIDITY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REMISSION; SYMPTOM; TREATMENT INDICATION; TREATMENT OUTCOME;

ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; DRUG COMBINATIONS; HUMANS;

EID: 0034523101     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018060-00006     Document Type: Article

References (77)

1. Epidemiology of asthma: The year in review
2. The burden of paediatric asthma
3. Changing prevalence of asthma in Australian children
4. Stabilization of asthma mortality
5. Surveillence for asthma- United States, 1960-1995
6. Patterns of asthma mortality in Philadelphia from 1969 to 1991
7. Age specific trends in asthma mortality in England and Wales, 1983-95: Results of an observational study
8. Reversing the trend: Reducing the prevalence of asthma
9. Changing prevalence of allergic rhinitis and asthma
10. Inhaled fluticasone propionate: A pharmacoeconomic review of its use in the management of asthma
11. Low-dose inhaled corticosteroids and the prevention of death from asthma
12. Cost-effectiveness of drug interventions
13. Asthma: From childhood to adulthood
14. A 15-year follow-up study of ventilatory function in adults with asthma
15. Mortality in adults with self-reported asthma
16. The natural history of asthma in adults: The problem of irreversibility
17. The economic impact of asthma and chronic obstructive pulmonary disease (COPD) in Sweden in 1980 and 1991
18. Cost estimates for chronic diseases
19. Cost-effectiveness analyses of salmeterol/fluticasone propionate combination product and fluticasone propionate in patients with asthma I: Introduction and overview
20. Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages <500μg/day in adults and adolescents with mild to moderate asthma
21. Trends in the cost of illness for asthma in the United States, 1985-1994
22. An economic evaluation of asthma in the United States
23. The costs of asthma
24. Analysis of direct, indirect, and total cost of asthma from patient survey data
25. Costs of asthma according to the degree of severity
26. A national estimate of the economic costs of asthma
27. Economics of asthma and asthma treatments
28. Quality-of-life in allergic diseases
29. Symptoms, quality of life, and health service contact among young adults with mild asthma
30. Fluticasone propionate improves quality of life in patients with asthma requiring oral corticosteroids
31. Discriminative aspects of two generic and two asthma-specific instruments: Relation with symptoms, bronchodilator use and lung function in patients with mild asthma
32. Evaluation of impairment of health related quality of life in asthma: Development of a questionnaire for use in clinical trials
33. The responsiveness of disease-specific and generic health measures to changes in the severity of asthma among adults
34. Salmeterol and fluticasone propionate in the treatment of asthma symptoms
35. 2-adrenergic bronchodilators and anti-inflammatory steroids in asthma
36. The complementary role of glucocorticosteroids and long-acting β-adrenergic agonists
37. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
38. Improving patient compliance with asthma therapy
39. Compliance in asthma
40. Compliance in asthma
41. Patient factors and compliance with asthma therapy
42. Effect of the inhaled route of administration on compliance in asthma
43. Inhaled salmeterol/fluticasone propionate combination: A review of its use in persistent asthma
44. Salmeterol/fluticasone propionate (50/500 μg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma
45. Combined salmeterol 50 μg and fluticasone propionate 250 μg in the Diskus device for the treatment of asthma
46. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled trial
47. Salmeterol/fluticasone propionate combination therapy 50/250 μg twice daily is more effective than budesonide 800 μg twice daily in treating moderate to severe asthma
48. Salmeterol/fluticasone combination inhaler: A new, effective and well tolerated treatment for asthma
49. Salmeterol and fluticasone propionate (50/250 μg) administered via combination Diskus inhaler: As effective as when given via separate Diskus inhalers
50. The salmeterol/fluticasone propionate combination (50/100mcg) via Diskus has a rapid onset of effect in asthma patients on salmeterol or inhaled corticosteroids
51. The salmeterol/fluticasone propionate (50/250mcg) dry powder combination Diskus has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma
52. Seretide (salmeterol 50mcg/fluticasone propionate 100mcg bid) compared with budesonide (400mcg bid) in mild to moderate asthma
53. A comparison of Advair/Seretide (salmeterol 50 μg/fluticasone propionate 250 μg bid) with formoterol 12 μg + budesonide 800 μg bid in moderate-severe asthma
54. A comparison of Advair/Seretide (salmeterol 50 μg/fluticasone propionate 250 μg bid) with formoterol 12 μg + budesonide 800 μg bid in moderate-severe asthma
55. Cost-effectiveness of salmeterol/fluticasone propionate combination product 50/250 μg twice daily and budesonide 800 μg twice daily in the treatment of adults and adolescents with asthma
56. National Asthma Education and Prevention Program working group report on the cost effectiveness of asthma care
57. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/100μg vs fluticasone propionate 100μg in adults and adolescents with asthma III: Results
58. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/250 μg vs fluticasone propionate 250 μg in adults and adolescents with asthma. IV: Results
59. Cost-effectiveness analysis of salmeterol/fluticasone propionate 50/500 μg vs fluticasone propionate 500 μg in patients with corticosteroid-dependent asthma V: Results
60. United HealthCare of Illinois: Working to improve asthma care
61. Cost-effectiveness of salmeterol/fluticasone combination product and budesonide bd in the United Kingdom (asthma)
62. Comparison of asthma treatment costs of salmeterol/fluticasone combination product 50/250mcg bid with budesonide 800mcg bid plus formoterol 12mcg bid
63. Measuring quality of life in asthma
64. Determining a minimal important change in a disease-specific quality of life questionnaire
65. Salmeterol/fluticasone propionate combination product improves quality of life in asthma patients
66. Combination of salmeterol/fluticasone propionate via Diskus improves quality of life in asthma patients
67. The British Guidelines on Asthma Management: 1995 review and position statement
68. Salmeterol: A review of its pharmacological properties and clinical efficacy in the management of children with asthma
69. Salmeterol xinafoate: A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease
70. Inhaled fluticasone propionate: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma
71. Costs and effects of inhaled corticosteroids and bronchodilators in asthma and chronic obstructive pulmonary disease